Urothelial Carcinoma Market on Track for Major Expansion by 2034, According to DelveInsight | Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics, BMS, Incyte, Abbisko

The Key Urothelial Carcinoma Companies in the market include - Merck, Bristol Myers Squibb, Bicycle Therapeutics, Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, Nektar Therapeutics, BMS, Incyte, Abbisko, Mamta Parikh, AstraZeneca, Janssen Research & Development, LLC, Pfizer, Inovio Pharmaceuticals, Hoffmann-La Roche, RemeGen Co., Ltd., and others.

DelveInsight's "Urothelial Carcinoma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Urothelial Carcinoma, historical and forecasted epidemiology as well as the Urothelial Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Urothelial Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Urothelial Carcinoma Market Forecast [https://www.delveinsight.com/sample-request/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Urothelial Carcinoma Market Report:

*
The Urothelial Carcinoma market size was valued ~USD 900 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In February 2025, Phase I findings for SHR-A2102 in individuals with advanced or metastatic urothelial carcinoma were presented at the 2025 ASCO Genitourinary Cancers Symposium.

*
In December 2024, China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd. 's SHR-A2102 has been proposed for designation as a breakthrough therapy. The drug is intended as a monotherapy for patients with locally advanced or metastatic urothelial carcinoma who have not responded to prior platinum-based chemotherapy and PD-(L)1 inhibitor treatment.

*
In September 2024, The Phase II findings for BL-B01D1 were shared during the 2024 ESMO Congress, highlighting its initial efficacy and safety in patients with locally advanced or metastatic urothelial carcinoma who had received prior treatments.

*
In August 2024, Mabwell Therapeutics, a biopharmaceutical company based in the US, has received authorization from China's National Medical Products Administration (NMPA) to initiate a Phase III clinical trial of 9MW2821 in combination with Toripalimab for the treatment of urothelial carcinoma. This randomized, open-label study will compare the effectiveness of 9MW2821 plus Toripalimab against the investigator's selected chemotherapy as a first-line treatment for patients with locally advanced or metastatic urothelial carcinoma.

*
During the forecast period (2024-2034), pipeline candidates like enfortumab vedotin+pembrolizumab plus-minus cisplatin/carboplatin, erdafitinib+cetrelimab, and durvalumab+SoC (cisplatin+gemcitabine/carboplatin+gemcitabine) plus-minus Tremelimumab are expected to contribute to the growth of the UCC market size.

*
In 2023, the United States held the largest share of the UCC market in the 7MM, representing nearly 70% of the market size compared to the EU4, the UK, and Japan.

*
In 2023, the United States reported the highest number of incident UCC cases, representing approximately 40% of the total global cases.

*
Among the EU4 and the UK, Germany had the highest number of UCC cases, followed by Italy, while the UK reported the fewest cases.

*
Key Urothelial Carcinoma Companies: Merck, Bristol Myers Squibb, Bicycle Therapeutics, Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, Nektar Therapeutics, BMS, Incyte, Abbisko, Mamta Parikh, AstraZeneca, Janssen Research & Development, LLC, Pfizer, Inovio Pharmaceuticals, Hoffmann-La Roche, RemeGen Co., Ltd., and others

*
Key Urothelial Carcinoma Therapies: KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), BT8009, Eganelisib + Opdivo, Infigratinib, Tislelizumab, Cyramza, Tecentriq, UGN-102, Bempegaldesleukin, Pemazyre (Pemigatinib), ABSK091/AZD4547, Selinexor, Tremelimumab, Erdafitinib, Niraparib, Atezolizumab, RC48-ADC, and others

*
The Urothelial Carcinoma epidemiology based on gender analyzed that Urothelial carcinoma in males has two-to-three fold greater incidence as compared to females

*
The Urothelial Carcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Urothelial Carcinoma pipeline products will significantly revolutionize the Urothelial Carcinoma market dynamics.

Urothelial Carcinoma Overview

When the cells that make up the urinary bladder develop into cancer, urothelial carcinoma begins. Any of the four bladder wall layers can give birth to bladder neoplasms. Over 95% of them are considered to be epithelial, while the remaining 5% are non-epithelial (mesenchymal). Urinary carcinomas are epithelial tumors that have differentiated towards normal urothelium.

Get a Free sample for the Urothelial Carcinoma Market Report:

https://www.delveinsight.com/report-store/urothelial-carcinoma-market [https://www.delveinsight.com/report-store/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Urothelial Carcinoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Urothelial Carcinoma Epidemiology Segmentation:

The Urothelial Carcinoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Urothelial Carcinoma

*
Prevalent Cases of Urothelial Carcinoma by severity

*
Gender-specific Prevalence of Urothelial Carcinoma

*
Diagnosed Cases of Episodic and Chronic Urothelial Carcinoma

Download the report to understand which factors are driving Urothelial Carcinoma epidemiology trends @ Urothelial Carcinoma Epidemiology Forecast [https://www.delveinsight.com/sample-request/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Urothelial Carcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Urothelial Carcinoma market or expected to get launched during the study period. The analysis covers Urothelial Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Urothelial Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Urothelial Carcinoma Therapies and Key Companies

*
KEYTRUDA (pembrolizumab): Merck

*
OPDIVO (nivolumab): Bristol Myers Squibb

*
BT8009: Bicycle Therapeutics

*
Eganelisib + Opdivo: Infinity

*
Infigratinib: QED Therapeutics

*
Tislelizumab: BeiGene

*
Cyramza: Eli Lilly

*
Tecentriq: Roche

*
UGN-102: UroGen

*
Bempegaldesleukin: NektarTherapeutics /BMS

*
Pemazyre (Pemigatinib): Incyte

*
ABSK091/AZD4547: Abbisko

*
Selinexor: Mamta Parikh

*
Tremelimumab: AstraZeneca

*
Erdafitinib: Janssen Research & Development, LLC

*
Niraparib: Pfizer

*
Atezolizumab: Inovio Pharmaceuticals

*
Atezolizumab: Hoffmann-La Roche

*
RC48-ADC: RemeGen Co., Ltd.

Discover more about therapies set to grab major Urothelial Carcinoma market share @ Urothelial Carcinoma Treatment Market [https://www.delveinsight.com/sample-request/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Urothelial Carcinoma Market Strengths

*
Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of advanced UC market

*
Strong pipeline activity with potential phase III and phase II emerging therapies

*
Presence of several approved therapies for the treatment of urothelial carcinoma patients.

Urothelial Carcinoma Market Opportunities

*
Rising incidence of cancer will provide the larger window of opportunity for new treatments

*
Reoccurrence is very common in cancers even after proper treatment. This opens up new window for pipeline activity

*
Increase in awareness and research of the indication, which provides a clearer aspect regarding potential options for treatment that can be explored by the key players

Scope of the Urothelial Carcinoma Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Urothelial Carcinoma Companies: Merck, Bristol Myers Squibb, Bicycle Therapeutics, Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics /BMS, Incyte, Abbisko, Mamta Parikh, AstraZeneca, Janssen Research & Development, LLC, Pfizer, Inovio Pharmaceuticals, Hoffmann-La Roche, RemeGen Co., Ltd., and others

*
Key Urothelial Carcinoma Therapies: KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), BT8009, Eganelisib + Opdivo, Infigratinib, Tislelizumab, Cyramza, Tecentriq, UGN-102, Bempegaldesleukin, Pemazyre (Pemigatinib), ABSK091/AZD4547, Selinexor, Tremelimumab, Erdafitinib, Niraparib, Atezolizumab, RC48-ADC, and others

*
Urothelial Carcinoma Therapeutic Assessment: Urothelial Carcinoma current marketed and Urothelial Carcinoma emerging therapies

*
Urothelial Carcinoma Market Dynamics: Urothelial Carcinoma market drivers and Urothelial Carcinoma market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Urothelial Carcinoma Unmet Needs, KOL's views, Analyst's views, Urothelial Carcinoma Market Access and Reimbursement

To know more about Urothelial Carcinoma companies working in the treatment market, visit @ Urothelial Carcinoma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Urothelial Carcinoma Market Report Introduction

2. Executive Summary for Urothelial Carcinoma

3. SWOT analysis of Urothelial Carcinoma

4. Urothelial Carcinoma Patient Share (%) Overview at a Glance

5. Urothelial Carcinoma Market Overview at a Glance

6. Urothelial Carcinoma Disease Background and Overview

7. Urothelial Carcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Urothelial Carcinoma

9. Urothelial Carcinoma Current Treatment and Medical Practices

10. Urothelial Carcinoma Unmet Needs

11. Urothelial Carcinoma Emerging Therapies

12. Urothelial Carcinoma Market Outlook

13. Country-Wise Urothelial Carcinoma Market Analysis (2020-2034)

14. Urothelial Carcinoma Market Access and Reimbursement of Therapies

15. Urothelial Carcinoma Market Drivers

16. Urothelial Carcinoma Market Barriers

17. Urothelial Carcinoma Appendix

18. Urothelial Carcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=urothelial-carcinoma-market-on-track-for-major-expansion-by-2034-according-to-delveinsight-infinity-qed-therapeutics-beigene-eli-lilly-roche-urogen-nektartherapeutics-bms-incyte-abbisko]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.